Figure 3.
Survival curves based on the expression of YTHDC2: (A) disease-free survival analysis in CRC patients from TMA, (B) overall survival analysis in CRC patients from TMA, (C) overall survival analysis in CRC patients from The Human Protein Atlas database. The median expression value was taken as the cut-off value and divided the patients into high YTHDC2 group and low YTHDC2 group.